Publication:
Total testosterone cut-off value indicating androgen-secreting tumor in premenopausal women with hirsutism

dc.contributor.authorGüneş, M.
dc.contributor.authorGüneş, E.
dc.contributor.authorÖztürk, F.
dc.contributor.buuauthorÖZTÜRK, FERDİ
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı
dc.contributor.orcid0000-0001-7659-7120
dc.contributor.researcheridG-2588-2013
dc.date.accessioned2024-11-28T12:54:03Z
dc.date.available2024-11-28T12:54:03Z
dc.date.issued2023-01-01
dc.description.abstractOBJECTIVE: There is insufficient data on which cut-off value must be used to measure the increase in total testosterone (TT) compared to the upper limit of normal (CULN) in the diagnosis of androgen-secreting tumor (ASTM) in female individuals with premenopausal hirsutism (FIPH).PATIENTS AND METHODS: A total of 413 FIPH over 18 years of age who were admitted to the endocrinology clinic between May 2013 and 30 April 2018 were eligible for the study. Hormone profiles of the participants in the follicular phase and other information were obtained from their files. The androgen suppression ratio (ASR) was analyzed after 48 hours of low-dose dexamethasone suppression test (LDDST) in those whose TT CULN (nmol/L) increased two-fold.RESULTS: Idiopathic hirsutism was found in 193 participants (46.73%) and polycystic ovary syndrome (PCOS) in 200 (48.43%) and other sources of hirsutism; non-classical congenital adrenal hyperplasia (NCCAH) in 10 patients (2.42%), hyperprolactinemia in 6 patients (1.45%), ASTM of ovarian origin in 2 patients (0.48%), Cushing's disease in 1 patient (0.24%), and adrenal ASTM in 1 patient (0.24%). A cutoff value of two-fold CULN increase for TT sensitivity of 100% and a specificity of 99.5% in indicating an ASTM source, and ASR above 49% in LDDST sensitivity of 80% and a specificity of 100% in excluding an ASTM source, was used.CONCLUSIONS: At the TT level, a two-fold increase CULN in FIPH indicates an ASTM source. In addition, ASR after LDDST is a useful parameter in the exclusion of ASTM sources in the same patient population.
dc.identifier.endpage8689
dc.identifier.issn1128-3602
dc.identifier.issue18
dc.identifier.startpage8681
dc.identifier.urihttps://hdl.handle.net/11452/48664
dc.identifier.volume27
dc.identifier.wos001097483700035
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherVerduci Publisher
dc.relation.journalEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPolycystic-ovary-syndrome
dc.subjectPrednisone
dc.subjectDiagnosis
dc.subjectDexamethasone
dc.subjectConsensus
dc.subjectCriteria
dc.subjectExcess
dc.subjectTotal testosterone
dc.subjectPolycystic ovary syndrome
dc.subjectAndrogen secreting tumor
dc.subjectNon-classical congenital adrenal hyperplasia
dc.subjectAndrogen suppression test with low dose dexamethasone
dc.subjectPharmacology & pharmacy
dc.titleTotal testosterone cut-off value indicating androgen-secreting tumor in premenopausal women with hirsutism
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı
local.indexed.atWOS
relation.isAuthorOfPublication74ecba84-bf60-41ea-a019-fdcb8d510a8f
relation.isAuthorOfPublication.latestForDiscovery74ecba84-bf60-41ea-a019-fdcb8d510a8f

Files